Facebook Linkedin Tumblr Twitter
Home Blog Page 13

Hudson Technologies, Inc. (NASDAQ:HDSN) Files An 8-K Other Events

By
ME Staff 8-k
-

Hudson Technologies, Inc. (NASDAQ:HDSN) Files An 8-K Other Events
Item 8.01

On June 29, 2021, Hudson Technologies, Inc. (the “Company”) issued a press release, attached hereto as Exhibit 99.1, announcing that the United States Defense Logistics Agency exercised its option to extend, for an additional five years to July 2026, the term of the Company’s existing five-year contract for sales to the Department of Defense.

(d) Exhibits

Exhibit 99.1 Press Release issued June 29, 2021.

 


HUDSON TECHNOLOGIES INC /NY Exhibit
SEC.gov | Request Rate Threshold Exceeded html {height: 100%} body {height: 100%; margin:0; padding:0;} #header {background-color:#003968; color:#fff; padding:15px 20px 10px 20px;font-family:Arial,…
To view the full exhibit click here

About Hudson Technologies, Inc. (NASDAQ:HDSN)

Hudson Technologies, Inc. is a refrigerant services company. The Company provides solutions to recurring problems within the refrigeration industry. Its products and services include refrigerant and industrial gas sales; refrigerant management services, which consist of reclamation of refrigerants, and RefrigerantSide services, which consist of system decontamination. Its refrigerant and industrial gas sales include selling of reclaimed and virgin (new) refrigerants to various customers in a range of segments of the air conditioning and refrigeration industry. It provides refrigerant management services, which also include laboratory testing through its laboratory, and banking services. It provides decontamination and recovery services that are performed at a customer’s site using its Zugibeast system under its RefrigerantSide services. The Company also participates in the generation of carbon offset projects as a component of its products and services.

Story continues below

3D PIONEER SYSTEMS, INC. (OTCMKTS:DPSM) Files An 8-K Entry into a Material Definitive Agreement

By
ME Staff 8-k
-

3D PIONEER SYSTEMS, INC. (OTCMKTS:DPSM) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

(d) Exhibits

Exhibit No. Description
10.1 Share Sale Agreement
99.1 Press Release issued June 24, 2021


3D PIONEER SYSTEMS, INC. Exhibit
EX-10.1 2 ex10-1.htm   EXHIBIT 10.1   Share Sale Agreement   BETWEEN   3D Pioneer Systems Inc.   AND Host Group of Companies Pty Ltd ACN 085 418 159   AND   Vantis Partners Pty Ltd ACN 142 953 731         This Acquisition Agreement (“Agreement”) is entered into this June of 23,…
To view the full exhibit click here

About 3D PIONEER SYSTEMS, INC. (OTCMKTS:DPSM)

3D Pioneer Systems, Inc. is engaged in implementing of three-dimensional (3D) printing in the gaming and entertainment industries. The Company provides 3D printing hardware, software and accessories. The Company’s Wyatt is a 3D printer with features, such as wireless connectivity, Web interface and remote mobile access, and control. The Company’s Appaloza is an online marketplace and platform for designing, collaborating and printing. The Company’s Appaloza is a 3D marketplace where both designs can be sold, shared, modified and printed. The Company’s Appaloza enables direct communication and control with fused deposition modeling (FDM) 3D printers on the market. The Company’s also offers The Whip, a Web enabled 3D printer controller. The Company is also engaged in developing a portfolio of mobile games playable on all platforms, including Internetwork Operating System (iOS), Android, Windows and Linux. The Company operates offices in the United States and the United Kingdom.

Story continues below

TECHPRECISION CORPORATION (OTCMKTS:TPCS) Files An 8-K Entry into a Material Definitive Agreement

By
ME Staff 8-k
-

TECHPRECISION CORPORATION (OTCMKTS:TPCS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01


TECHPRECISION CORP Exhibit
EX-10.1 2 tm2120896d1_ex10-1.htm EXHIBIT 10.1     Exhibit 10.1     AMENDMENT TO AMENDED AND RESTATED LOAN PURCHASE AND SALE AGREEMENT   THIS AMENDMENT TO AMENDED AND RESTATED LOAN PURCHASE AND SALE AGREEMENT (the “Amendment”),…
To view the full exhibit click here

About TECHPRECISION CORPORATION (OTCMKTS:TPCS)

TechPrecision Corporation is a manufacturer of fabricated and machined metal components and systems. The Company offers a range of services required to transform metallic raw materials into precision finished products. It sells finished products to its customers in three industry groups: defense, energy and precision industrial. Its primary business includes the business of its subsidiary, Ranor, Inc. Its operations in China are conducted through its subsidiary, Wuxi Critical Mechanical Components Co., Ltd. (WCMC). WCMC, through its subcontractors, provides precision component fabrication and machining solutions. Its manufacturing solutions include fabrication operations (cutting, press and roll forming, assembly, welding, heat treating, blasting and painting), and machining operations, including computer numerical controlled horizontal and vertical milling centers. Its projects include the manufacturing of products from various traditional, as well as specialty metal alloys.

Story continues below

DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Unregistered Sales of Equity Securities

By
ME Staff 8-k
-

DELCATH SYSTEMS, INC. (NASDAQ:DCTH) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities.

As of June 28, 2021, the outstanding shares of common stock, $0.01 par value per share (the “Common Stock”) of Delcath Systems, Inc. (the “Company”) had increased by more than 5% since the last reported shares of Common Stock outstanding.

As of June 28, 2021, the Company had 7,349,777 shares of Common Stock issued and outstanding. The increase in outstanding shares of Common Stock is due to (i) the conversion of 7,651.35 shares of Series E Convertible Preferred Stock into 765,135 shares of Common Stock, (ii) the conversion of 1,122.44 shares of Series E-1 Convertible Preferred Stock into 112,244 shares of Common Stock (iii) the exercise of 3,750 Series F warrants to purchase 3,750 shares of Common Stock, (iv) the exercise of 4,341 Series E and E-1 warrants to purchase 4,341 shares of Common Stock and (v) the exercise of 215,000 pre-funded warrants to purchase 215,000 shares of Common Stock.

About DELCATH SYSTEMS, INC. (NASDAQ:DCTH)

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Story continues below

DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Files An 8-K Submission of Matters to a Vote of Security Holders

By
ME Staff 8-k
-

DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Files An 8-K Submission of Matters to a Vote of Security Holders

About DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN)

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company’s Diffusion’s technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.

Story continues below

EVOKE PHARMA, INC. (NASDAQ:EVOK) Files An 8-K Other Events

By
ME Staff 8-k
-

EVOKE PHARMA, INC. (NASDAQ:EVOK) Files An 8-K Other Events
Item 8.01.  Other Events.

On June 29, 2021, Evoke Pharma, Inc. (“Evoke” or the “Company”), EVERSANA, the Company’s commercialization partner, and The International Foundation for Gastrointestinal Disorders (“IFFGD”), announced Evoke’s membership into IFFGD Industry Council. Evoke will join a likeminded group of organizations and brands focused on bettering patients affected by gastrointestinal disorders. As part of the Industry Council, Evoke will participate in biannual council meetings to gain industry insights and provide feedback on future plans for IFFGD.

In addition to the Industry Council, Evoke is excited to sponsor the IFFDG’s upcoming 30th Anniversary Digestive Health Virtual Walk in August 2021 during Gastroparesis Awareness Month. This walk is a unique fitness event which will provide participants with an opportunity to engage at their own pace and as their health and schedules permit. To honor the thirty years of the IFFGD’s existence, the overall campaign goal is for all participants to collectively walk 10,950 miles over two weeks. Goals will also go beyond physical fitness by encouraging participants to participate in activities that promote general wellness such as scheduling a doctor’s appointment, trying a new gut friendly recipe or starting a log of their meals and/or symptoms.

Safe Harbor Statement

The Company cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include statements regarding the Company’s plans to increase awareness of gastrointestinal disorders. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including those described in the Company’s periodic filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

About EVOKE PHARMA, INC. (NASDAQ:EVOK)

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Story continues below

USA EQUITIES CORP. (OTCMKTS:USAQ) Files An 8-K Regulation FD Disclosure

By
ME Staff 8-k
-

USA EQUITIES CORP. (OTCMKTS:USAQ) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On June 29, 2021, USA Equities Corp. (the “Company”) issued a press release entitled “USA Equities Corp Announces the signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services.”

A copy of the above-mentioned press release is attached herewith as Exhibit 99.1.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website (https://usaqcorp.com), press releases, and various social media channels, including its Twitter account (https://twitter.com/USAQcorp), its LinkedIn account (https://www.linkedin.com/company/usaqcorp) its Facebook account (https://www.facebook.com/USA-Equities-100113722270622), and its Instagram account (https://www.instagram.com/usaqcorp/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.

ITEM 9.01 Financial Statements and Exhibits

99.1 Press release dated June 29, 2021 entitled “USA Equities Corp Announces the signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services.”


USA EQUITIES CORP. Exhibit
EX-99.1 2 ex99-1.htm   EXHIBIT 99.1     USA Equities Corp Announces the Signing of a Distribution Agreement with a Prominent Physician Management Services Firm For its AllergiEnd® Products and Services   -Continued Momentum Expanding Independent Care Practitioner Network-   West Palm Beach,…
To view the full exhibit click here

About USA EQUITIES CORP. (OTCMKTS:USAQ)

USA Equities Corp., formerly American Biogenetic Sciences, Inc., is a shell company. The Company focuses to seek new business opportunities, including seeking an acquisition or merger with an operating company. The Company’s subsidiary, USA Equities Trust, Inc., is engaged in acquiring real estate. The Company was engaged in the research, development and marketing of cardiovascular and neurobiology products for the purpose of commercial development and vaccines distribution. The Company’s products were designed for in vitro and in vivo diagnostic procedures and therapeutic drugs, and its products had been identified for use in the treatment of epilepsy, migraine and mania, neurodegenerative diseases, coronary artery diseases and cancer. The Company has no operations.

Story continues below

Integrity Applications, Inc. (OTCMKTS:IGAP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

By
ME Staff 8-k
-

Integrity Applications, Inc. (OTCMKTS:IGAP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 22, 2021, Luis J. Malavé has been appointed to the Company’s Board of Directors.

Mr. Malavé brings more than 30 years of leadership experience in the MedTech industry, primarily in diabetes management, spanning all company stages, from private startups to large-cap publicly listed companies. He has extensive expertise in product development, operations, marketing, strategic partnerships, and US FDA regulatory strategy.

Since October 2017, Mr. Malavé has served as President of EOFLOW CO. Ltd., a company listed on the Korea Stock Exchange that has developed a wearable disposable insulin pump. From October 2014 to June 2016, he was COO of Mikroscan Technologies. Prior to that, Mr. Malavé was the President and CEO of Palyon Medical, maker of an implantable drug-delivery system that spun out from German medical-technology giant Fresenius SE. Prior to Palyon, he spent nearly a decade at insulin pump maker Insulet Corp., including as its Senior Vice President of Research, Development and Engineering, and as Chief Operating Officer. He also held various senior positions at Medtronic and MiniMed, overseeing product development of various diabetes management devices.

Mr. Malavé earned his Bachelor’s degree in Mathematics and Computer Science from the University of Minnesota, a Master’s degree in Software Engineering from the University of St. Thomas, and an MBA from the University of Maryland.


About Integrity Applications, Inc. (OTCMKTS:IGAP)

Integrity Applications, Inc. is a medical device company. The Company is focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by persons suffering from diabetes. It has developed a non-invasive blood glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The Company operates in Europe, and Asia and Pacific. The GlucoTrack model DF-F utilizes a combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute through a small sensor that is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing blood.

Story continues below

Corp. (OTCMKTS:CCYPQ) Files An 8-K Termination of a Material Definitive Agreement

By
ME Staff 8-k
-

Corp. (OTCMKTS:CCYPQ) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02 TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT

On June 22, 2021, the Board of Directors of Hammer Fiber Optics Holdings Corp. (“the Company”) held a special meeting of the Board of Directors to discuss the matter of renewal regarding the employment contract of Erik B. Levitt, President and Chief Executive Officer of the Company. The contract is due to expire on September 30th, 2021, with a requirement to provide a notice period of 90 days to Mr. Levitt regarding the Board’s decision to either terminate or extend under the existing terms. The Board unanimously voted not to renew the contract, with Mr. Levitt abstaining from the vote. The context for this decision by the Board of Directors is summarized in Item 8.01 hereunder.

 

Mr. Levitt’s employment as the Company’s Chief Executive under the agreement will terminate on September 30th, 2021. Mr. Levitt will continue in his role as a Director of the Company, as the Principal Financial Officer and as the CEO of the 1stPoint Communications and Endstream Communications subsidiaries, respectively, as further described in Item 8.01.

 

Item 8.01 OTHER EVENTS

Over the past 12 months, the management of Hammer Fiber Optics Holdings Corp. has focused on eliminating debt on the balance sheet of the company since the retraction by Verizon of the licensed spectrum within the 28GHz frequency where the Company designed and deployed innovative broadband technology to cater for its wireless broadband initiative. The cancellation of this license led to defaults on long term service contracts entered into that provided the backbone fiber connectivity to the tower infrastructure of the Company and as such, approximately $4M worth of liabilities were recorded on the balance sheet due to the acceleration of these contracts by the relevant service providers. Following intensive negotiation by the Company’s executive management, these liabilities have been settled in full and the associated liabilities have now been wiped off the balance sheet as recorded in the most recent Form 10-Q filings of the Company.

 

Senior management and the Board of Directors have over the past two years been reevaluating its future wireless broadband strategy and have been making meaningful strides into the rebuilding of its wireless assets and initiatives. The acquisition of the 1stPoint subsidiaries has made this possible and the deployment of wireless broadband services to regions such as Huntsville, Alabama is now well underway. Notwithstanding, the Directors of the Company have actively, over the past two years, researched opportunities that would materially increase shareholder value and as such, have come to the conclusion that the Company would need to implement a diversification strategy into related industry verticals. Since the establishment of the Company’s African broadband initiative which culminated in the incorporation of Hammer Wireless [SL] Ltd, it has become apparent the future success of this initiative would require the full payment for services rendered to broadband customers to be received largely in advance. Consequently, the idea of establishing a method of prepayment of services rendered to local African customers by their family members living abroad [commonly known as remittances] was strongly considered. To cater for this requirement, the Company has explored the idea of developing a FINTECH initiative, consequently providing the group an opportunity to further diversify its strategy.

 

The Company, being desirous of expanding its product offerings across a broader range of related market sectors, has considered entry into the Remittance market serving Africa as it has become extremely opportunistic, representing a market sector of approximately $58 Billion annually in remittance activity. To this end, The Company has entered into negotiation with various financial institutions and FINTECH product developers to create a product offering that would position the Company as a meaningful participant in this extremely lucrative market sector. The diversification strategy into a broader segment of related industry verticals such as cross border bill payment and money remittances and the on-going negotiations between the Board of the Company and that of International FINTECH developers and financial institutions, requires the restructuring of the role of the current management and Board of Directors.

 

Accordingly, the board has explored a strategy whereby the role of the Chief Executive Officer would reside within each active subsidiary or business vertical to make way for the addition of new acquisitions to the Company. Each potential acquisition will require the associated Chief Executive Officer to report to the Board of the Company independently and as such the current Chief Executive role at the parent level will be eliminated. To this end, the employment contract of Mr. Erik B. Levitt, the current Chief Executive Officer, will expire at the end of its three-year term as of September 30th, 2021, to enable the Board to prepare for its diversification strategy. Mr. Levitt will remain an active member of the Board of Directors and will participate in the restructuring initiative of the Company.

 

Story continues below

PHI GROUP, INC. (OTCMKTS:PHIL) Files An 8-K Regulation FD Disclosure

By
ME Staff 8-k
-

PHI GROUP, INC. (OTCMKTS:PHIL) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure

The information in this Item 7.01 of this Current Report is furnished to Item 7.01 and shall not be deemed “filed’ for any purpose, including for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act regardless of any general incorporation language in such filing.

I. Extension of Repurchase Date for the Company’s Common Stock

On June 25, 2021, the Board of Directors of PHI Group, Inc., a corporation originally incorporated in the State of Nevada on June 08, 1982 and redomiciled in the State of Wyoming on September 20, 2017 (the “Company”), adopted the following resolutions in lieu of a meeting:

WHEREAS, on December 28, 2020 the Company’s Board of Directors passed a corporate resolution to extend the time period for the repurchase of its own shares of common stock from the open market from time to time in accordance with the terms mentioned below:


PHI GROUP INC Exhibit
SEC.gov | Request Rate Threshold Exceeded html {height: 100%} body {height: 100%; margin:0; padding:0;} #header {background-color:#003968; color:#fff; padding:15px 20px 10px 20px;font-family:Arial,…
To view the full exhibit click here

About PHI GROUP, INC. (OTCMKTS:PHIL)

PHI Group, Inc. is engaged in mergers and acquisitions. The Company focuses on acquiring operating businesses in selective industries and invests in various ventures that may create long-term value for its shareholders. In addition, the Company also provides corporate finance services, including merger and acquisition advisory and consulting services for client companies through its subsidiary, PHI Capital Holdings, Inc. The Company’s business involves acquisitions of energy assets, as well as production and trading of energy commodities. The Company will continue to pursue its merger and acquisition program by acquiring all or controlling interests in target companies in various industries, including but not limited to conventional energy, renewables, natural resources, agribusiness, technology, transportation, education, distribution, mining, oil and gas, financial Services, healthcare and pharmaceuticals.

Story continues below
1...121314...14,628Page 13 of 14,628

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© Market Exclusive 2019